#USA #San Rafael #BioMarin #VOXZOGO #Hypochondroplasia

New Developments in Hypochondroplasia Treatment: VOXZOGO Phase 3 Results

BioMarin Pharmaceutical Inc. has recently made headlines with its positive Phase 3 trial results for VOXZOGO® (vosoritide), a groundbreaking treatment aimed at children diagnosed with hypochondroplasia. This milestone was marked by the publication of the CANOPY-HCH-3 study findings in the New England Journal of Medicine (NEJM) Evidence and presented during the European Society for Paediatric Endocrinology’s (ESPE) 2026 Annual Meeting.

Summary of Results

The CANOPY-HCH-3 trial provided compelling evidence that VOXZOGO significantly enhances growth parameters in children suffering from hypochondroplasia. The treatment demonstrated statistically significant improvements across various metrics, including:

• - Annualized growth velocity (AGV): A noteworthy increase of 2.33 cm/year compared to the placebo (p < 0.0001).
• - Standing height: An average increase of 2.35 cm (p < 0.0001).
• - Height Z-score: Improvements reflected a mean change of 0.39 standard deviations (p < 0.0001).
• - Arm span: A significant increase of 1.03 cm was also recorded (p = 0.0082).

These results not only meet the primary endpoint of the trial but also indicate potential quality of life enhancements for children receiving VOXZOGO. Parents and caregivers noted substantial improvements in daily functioning, supporting the drug's therapeutic potential.

The Scientific Basis Behind VOXZOGO

Hypochondroplasia, a rare genetic condition characterized by stunted bone growth, affects a child’s overall stature and physical abilities. Compared to more common growth disorders like achondroplasia, hypochondroplasia presents unique challenges and often requires tailored treatment approaches. VOXZOGO, an analog of the C-type natriuretic peptide (CNP), is engineered to positively modulate the FGFR3 signaling pathway implicated in endochondral bone growth, thereby promoting better growth outcomes.

Implications for Future Treatment

As a result of these promising findings, BioMarin has submitted a supplemental New Drug Application (sNDA) to the FDA. If approved, VOXZOGO will become the first targeted therapy available for children suffering from hypochondroplasia, with market availability anticipated in 2027.

Dr. Greg Friberg, Executive Vice President and Chief Research & Development Officer at BioMarin, emphasized the importance of this study, stating, "These detailed results significantly enhance our understanding of VOXZOGO’s impact on multiple growth parameters in children with hypochondroplasia."

Addressing Challenges in Hypochondroplasia

The journey to diagnosis and suitable treatment for hypochondroplasia can often be complicated for families. Many parents navigate a maze of medical evaluations and emotional hurdles before receiving adequate support. Dr. Andrew Dauber, the lead investigator of the study, shared, "Hypochondroplasia can profoundly affect a child's growth, physical interaction, and overall quality of life. This treatment presents hope for many families facing the complexities of this condition."

Conclusion

With an estimated 14,000 children diagnosed with hypochondroplasia potentially eligible for VOXZOGO treatment globally, the ongoing commitment of BioMarin to further clinical assessments and regulatory engagements is likely to open doors for innovative therapies in the future. As the healthcare community, regulators, and families await drug approval, the Phase 3 trial results herald a new era of hope and treatment possibilities for children affected by hypochondroplasia.

For additional information on clinical trials and updates regarding VOXZOGO, interested parties can visit BioMarin’s clinical trials page.